
Obstructive Sleep Apnea- Pipeline Insight, 2024
Description
Obstructive Sleep Apnea- Pipeline Insight, 2024
DelveInsight’s, “Obstructive Sleep Apnea- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Obstructive Sleep Apnea: Overview
Obstructive sleep apnea (OSA) is characterized by episodes of breathing cessation or shallow breathing in sleep. These episodes are due to complete or partial collapse of upper airway. Most of the time, the respiratory events are associated with snoring, oxygen desaturations and brief arousal from sleep. Sleep apnea is usually worse during supine and Rapid Eye Movement (REM) sleep. There could be exacerbation of snoring and OSA with alcohol consumption or ingestion of sedative medications. OSA is common and the prevalence is increasing with the increased prevalence of obesity. Daytime sleepiness is among the most common symptoms, but many patients with OSA are asymptomatic. Patients with OSA who are asymptomatic, or whose symptoms are minimally bothersome and pose no apparent risk to driving safety, can be treated with behavioral measures, such as weight loss and exercise. Common obstructive sleep apnea warning signs include: Daytime sleepiness or fatigue, dry mouth or sore throat when person wake up ,headaches in the morning ,trouble concentrating, forgetfulness, depression, or crankiness, night sweats, restlessness during sleep. Complications of obstructive sleep apnea can include: Sleepiness during the day and trouble concentrating. Adults may have a higher risk of accidents, and children may have a hard time at school. Cardiovascular problems such as heart attack, high blood pressure, unusual heart rhythms, or stroke, eye problems such as glaucoma and dry eye and metabolic disorders like type 2 diabetes. The prevalence of symptomatic OSA or OSA syndrome was only 2% in women versus 4% in men. Obesity is a major risk factor for OSA. OSA is seen in up to 70% of morbidly obese individuals. Other risk factors include advancing age and craniofacial deformities. OSA is also common in smokers, individuals with family history of OSA and in postmenopausal females. Prevalence of OSA increases with coexisting medical conditions like – pregnancy, atrial fibrillation, stroke, congestive heart failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), hypothyroidism, and Polycystic Ovary Syndrome (PCOS).
""Obstructive Sleep Apnea- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obstructive Sleep Apnea pipeline landscape is provided which includes the disease overview and Obstructive Sleep Apnea treatment guidelines. The assessment part of the report embraces, in depth Obstructive Sleep Apnea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea.
This segment of the Obstructive Sleep Apnea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obstructive Sleep Apnea Emerging Drugs
- Lemborexant : Eisai
- Sulthiame : Desitin Arzneimittel GmbH
- AD 182 : Apnimed
- TAK-925 : Takeda
Further product details are provided in the report……..
Obstructive Sleep Apnea: Therapeutic Assessment
This segment of the report provides insights about the different Obstructive Sleep Apnea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Obstructive Sleep Apnea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Obstructive Sleep Apnea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obstructive Sleep Apnea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obstructive Sleep Apnea drugs.
Obstructive Sleep Apnea Report Insights
- Obstructive Sleep Apnea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Obstructive Sleep Apnea drugs?
- How many Obstructive Sleep Apnea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Obstructive Sleep Apnea and their status?
- What are the key designations that have been granted to the emerging drugs?
- Apnimed
- Therapix Biosciences
- Eisai
- Idorsia Pharmaceuticals
- Takeda
- Merck & Co
- Taisho Pharmaceutical Co., Ltd.
- Bayer
- Janssen Pharmaceuticals
- RespireRx Pharmaceuticals
- Cortex Pharmaceuticals
- Michael James Enterprises
- AD036
- THX-110
- Lemborexant
- AD182
- AD504
- AD109
- TAK-925
- TS-142
- BAY2586116
- Dronabinol low-dose
- CX 1739
Table of Contents
110 Pages
- Introduction
- Executive Summary
- Obstructive Sleep Apnea: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Obstructive Sleep Apnea– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Sulthiame : Desitin Arzneimittel GmbH
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Obstructive Sleep Apnea Key Companies
- Obstructive Sleep Apnea Key Products
- Obstructive Sleep Apnea- Unmet Needs
- Obstructive Sleep Apnea- Market Drivers and Barriers
- Obstructive Sleep Apnea- Future Perspectives and Conclusion
- Obstructive Sleep Apnea Analyst Views
- Obstructive Sleep Apnea Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.